Recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment NCT06589804 Conditions Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more Locations University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States Fremont - Rideout Cancer Center — Marysville, California, United States VA Palo Alto Health Care System — Palo Alto, California, United States UCHealth Memorial Hospital Central — Colorado Springs, Colorado, United States View all 192 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 Conditions Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +48 more Locations Providence Hospital — Mobile, Alabama, United States University of South Alabama Mitchell Cancer Institute — Mobile, Alabama, United States Fairbanks Memorial Hospital — Fairbanks, Alaska, United States Mercy Hospital Fort Smith — Fort Smith, Arkansas, United States View all 781 locations View more locations Show fewer locations Loading locations... View Trial Details
